|
|
Dermatologists' Case
Files:
Immune Response Modifier Therapy Used With Good Results in Recalcitrant Warts and Photoaging
A supplement to Skin & Allergy
News, supported by an educational grant from 3M
Pharmaceuticals and designated by the American Academy of
Dermatology (AAD) for AAD continuing medical educational
(CME) credit.
Topics
- Introduction
- Photodamage in a 46-Year-Old
Woman
- Man With a Large Plantar Wart
- Recalcitrant Periungual Warts in a
12-Year-Old
Boy
|
Faculty
Cheryl L. Effron, MD
Private Practice
Anaheim Hills, Calif.
Albert M. Kligman, MD, PhD
Professor Emeritus of Dermatology
University of Pennsylvania School of Medicine
Philadelphia, PA.
Robert B. Skinner, Jr., MD
Professor of Medicine (Dermatology)
The University of Tennessee
Health Science Center
Memphis, TN
|
Back to top  |
Faculty
Disclosures
The faculty of this CME activity
disclose the following:
| Faculty Member |
|
|
|
Cheryl L. Effron,
MD |
Dr. Effron is on the Speaker’s
Bureau and the Aldara Advisory Panel at 3M
Pharmaceuticals. She refers to a discussion elsewhere in
this supplement of the unlabeled use of imiquimod for the prevention of
AKs and for the treatment of plantar and periungual warts. |
|
Albert M. Kligman, MD,
PhD
|
Dr. Kligman
has no financial disclosures. He discusses the unlabeled use
of imiquimod for the prevention of
AKs. |
|
Robert B. Skinner, Jr.,
MD
|
Dr. Skinner is on the
Speaker’s Bureau and the Aldara Advisory Panel at 3M
Pharmaceuticals. He discusses the unlabeled use of
imiquimod for the treatment of plantar and periungual
warts. |
| |
| Back to top |
Target Audience
This activity has been developed for
dermatologists and other healthcare professionals involved
in the diagnosis and treatment of skin conditions for which
immune response modifier (IRM) therapy may
be considered. |
Educational
Needs
Actinic keratoses (AKs) and common warts are lesions that are difficult to eliminate. Traditional therapies—surgical and topical chemical modalities—can be effective, but none of these has been shown to produce remission in all patients.
IRM therapy is a relatively recent approach to eliminating AKs and lesions caused by human papillomavirus (HPV). In both cases, topical imiquimod—the first agent in the class of IRMs—causes an upregulation of several mechanisms that control local immune system function.
To date, imiquimod has been approved by the US Food and Drug Administration for the treatment of anogenital warts, superficial basal cell carcinoma, and AKs of the face and balding scalp. In the cases presented here, imiquimod was used investigationally as a potential prophylactic treatment for AKs in patients with photodamaged facial skin who, by definition, are at increased risk for AKs and, possibly, subsequent squamous cell carcinoma. In the cases of common warts, imiquimod was used based on the efficacy of this agent in treating anogenital warts, also caused by infection with HPV.
The results of well-controlled clinical
trials form the foundation of any evidence-based approach to
medical treatment. In treating individual patients, however,
clinicians also receive valuable knowledge from their own
experience and that of their colleagues. Using case studies
as a basis, this supplement offers the clinical experiences
of experts who have used imiquimod in a variety of skin
diseases. |
| Back to top |
Learning Objectives
By reading and studying this
supplement, participants should be able to:
·
Briefly summarize what is currently understood about the antiviral and antitumor properties and mechanism of action of imiquimod.
·
Describe the experience of a clinician who treated a patient enrolled in a study involving the use of imiquimod to prevent the emergence of subclinical AKs.
·
Discuss the experience of a clinician who used imiquimod to treat two patients with recalcitrant warts—one with a plantar wart and one with periungual warts of the fingers.
|
| Back to top |
CME
Recognition
This Skin & Allergy News
supplement is recognized by the American Academy
of Dermatology (AAD) for 1 hour of AAD Category 1 CME credit
and may be used toward the American Academy of Dermatology’s
Continuing Medical Education Award.
This program was developed in
accordance with the Accreditation Council for Continuing
Medical Education guidelines.
Term
of Approval: June 2006—May 31, 2007
Copyright
© 2006 Elsevier Inc.
|